Sri Lankan Physicians Raise Concerns Over SARS-CoV-2 Infections and Potential Macroamylasemia Risk

Elevated amylase levels in COVID-19 patients have raised concerns about potential pancreatic issues. However, a recent case study suggests an alternative explanation: macroamylasemia.

Amylase, an enzyme involved in carbohydrate digestion, is primarily produced by the pancreas and salivary glands. This case report reveals that macroamylasemia, a rare and benign condition, may be a hidden culprit behind elevated amylase levels in some COVID-19 patients.

Macroamylasemia is characterized by the formation of macromolecular complexes between serum amylase and other proteins, preventing its elimination through urine. This condition often leads to persistently high amylase levels in the blood.

The study highlights the importance of considering alternative diagnoses in COVID-19 patients with elevated amylase levels. It is crucial to rule out potentially severe conditions like acute pancreatitis, which can worsen COVID-19 outcomes.

To diagnose macroamylasemia, physicians can employ the amylase-creatinine clearance ratio, a simple and cost-effective screening test. A ratio of less than 1% is suggestive of macroamylasemia, while over 5% indicates acute pancreatitis.